As Congress considered a bill to reauthorize the Office of National Drug Control Policy (ONDCP), the U.S. Government Accountability Office was asked to discuss in testimony before the Committee on Oversight and Government Reform, House of Representatives, federal agencies' specific opioid-related strategies and the extent to which each agency is measuring its performance, as well as federal agencies' efforts to enhance collaboration and information sharing to limit the availability of illicit opioids, ongoing challenges to doing so, and ONDCP's role in enhancing such collaboration.